Clinical Trial

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

Study acronym: Falcon-HD
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-02
Trial Details
NCT Number NCT06873334
Lead Sponsor Skyhawk Therapeutics, Inc.
Conditions Huntington Disease, Huntingtons Disease
Enrollment 120 participants
Start Date 2025-05-27
Primary Completion 2027-05 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-01